Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Delouvrie
Benedicte Delouvrie, Reims FR
| Patent application number | Description | Published |
|---|---|---|
| 20090062267 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS - The present invention relates to compounds that inhibit a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins. | 03-05-2009 |
| 20090203663 | CHEMICAL COMPOUNDS - The present invention relates to compounds that inhibit a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins. | 08-13-2009 |
Benedicte Delouvrie, Macclesfield GB
| Patent application number | Description | Published |
|---|---|---|
| 20090118305 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 - The invention concerns pyridine and pyrazine derivatives of Formula I | 05-07-2009 |
Benedicte Delouvrie, Reims Cedex 2 FR
| Patent application number | Description | Published |
|---|---|---|
| 20080255183 | N-[HETEROARYLCARBONYL]-3-THIENYL-L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS - The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to a5b1 antagonists that also exhibit appropriate selectivity profile(s) against other integrins. | 10-16-2008 |